Uloric Lawsuit

Preliminary study results indicate that Uloric is associated with a higher risk of death compared to other gout medications. Filing a Uloric lawsuit may be an option if someone you love died while taking this drug.

Uloric Case Evaluations

The defective drug attorneys at Bernstein Liebhard LLP are offering free, no-obligation case reviews to individuals interested in filing a Uloric lawsuit on behalf of a deceased loved one. To learn more, please contact our office by calling (888) 994-5118.

Uloric Heart Side Effects

Uloric (febuxostat) is indicated to treat adults suffering from gout, a form of arthritis caused by excessive amounts of uric acid in the blood.

Uloric is manufactured by Takeda Pharmaceuticals, which obtained U.S. Food & Drug Administration (FDA) approval to market the drug in 2009.

Uloric’s pre-approval clinical trials indicated that patients treated with febuxostate were more likely to experience heart related problems compared to those treated with another gout drug called allopurino (Zyloprim and Aloprim). As such, the label for Uloric currently includes a “Warning and Precaution” regarding the potential for cardiovascular events, including:

  • Heart attacks
  • Strokes
  • Heart-related deaths

The FDA also ordered Takeda to conduct an additional post-market safety study to better understand these findings.

Uloric Cardiac Death

The FDA announced the conclusion of Takeda’s post-market Uloric study in November 2017.

According to the agency, the study involved more than 6,000 adults who underwent treatment for gout with either Uloric or allopurino. The trial’s primary outcome was a combination of heart-related death, non-deadly heart attack, non-deadly stroke, and a condition of inadequate blood supply to the heart requiring urgent surgery.

“The preliminary results show that overall, febuxostat did not increase the risk of these combined events compared to allopurinol,” the FDA said in a Drug Safety Communication published on November 15, 2017.  “However, when the outcomes were evaluated separately, febuxostat showed an increased risk of heart-related deaths and death from all causes.

The FDA will conduct a comprehensive review once it receives the final results of the Uloric study from Takeda. In the meantime, the agency is advising patients to discuss any concerns with their doctor. They should not stop taking Uloric without first consulting with their health care provider.

Health care professionals should consider this safety information when deciding whether to prescribe or continue patients on Uloric.

Learn if You’re Eligible to File a Uloric Lawsuit

You may be entitled to financial compensation if someone you loved died while taking Uloric, including payment for:

  • Wrongful death
  • Medical bills
  • Loss of future earnings
  • Pain and suffering
  • Emotional distress
  • More

To learn if you are eligible to file a Uloric lawsuit, please call (888) 994-5118 to arrange for your free, no-obligation legal review.

  1. Takeda Pharmaceuticals, Inc. (2009) “Uloric: Highlights of Prescribing Information” https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021856s011lbl.pdf
  2. FDA (2017) “FDA Drug Safety Communication: FDA to evaluate increased risk of heart-related death and death from all causes with the gout medicine febuxostat (Uloric)” https://www.fda.gov/Drugs/DrugSafety/ucm584702.htm
Last Modified: May 16, 2018

Get the latest news and litigation updates about this case by following us on Facebook. Click the "Like" button below.


Follow Us

RXInjuryHelp.com on Google+  RXInjuryHelp.com on Facebook  RXInjuryHelp.com on LinkedIn  RXInjuryHelp.com on Twitter  RXInjuryHelp.com on YouTube  RXInjuryHelp.com on Pinterest